|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 血管内超声去肾交感神经术治疗高血压:一项多中心,国际,单盲,随机,假手术对照试验显示文摘早期研究表明,基于射频的去肾交感神经术可降低中度高血压患者的血压。研究者研究了在没有使用抗高血压药物的情况下,使用血管内超声去。肾交感神经术是否会降低高血压患者的动态血压。 | 刘青 叶鹏 Azizi M Schmieder RE Mahfoud F Weber MA Daemen J Davies J Basile J Kirtane AJ Wang Y Lobo MD Saxena M Feyz L Rader F Lurz P Sayer J Sapoval M Levy T Sanghvi K Abraham J Sharp ASP Fisher NDL Bloch MJ Reeve-Stoffer H Coleman L Mullin C Mauri L | 2018 | 中华高血压杂志2018，26，10： | 27 |
| 2 | Renal sympathetic denervation in therapy resistant hypertension-pathophysiological aspects and predictors for treatment success显示文摘Many forms of human hypertension are associated with an increased systemic sympathetic activity. Especially the renal sympathetic nervous system has been found to play a prominent role in this context. Therefore, catheterinterventional renal sympathetic denervation(RDN) has been established as a treatment for patients suffering from therapy resistant hypertension in the past decade. The initial enthusiasm for this treatment was markedly dampened by the results of the Symplicity-HTN-3 trial, although the transferability of the results into clinical practice to date appears to be questionable. In contrast to the extensive use of RDN in treating hypertensive patients within or without clinical trial settings over the past years, its effects on the complex pathophysiological mechanisms underlying therapy resistant hypertension are only partly understood and are part of ongoing research. Effects of RDN have been described on many levels in human trials: From altered systemic sympathetic activity across cardiac and metabolic alterations down to changes in renal function. Most of these changes could sustainably change long-term morbidity and mortality of the treated patients, even if blood pressure remains unchanged. Furthermore, a number of promising predictors for a successful treatment with RDN have been identified recently and further trials are ongoing. This will certainly help to improve the preselection of potential candidates for RDN and thereby optimize treatment outcomes. This review summarizes important pathophysiologic effects of renal denervation and illustrates the currently known predictors for therapy success. | Karl Fengler Karl Philipp Rommel Thomas Okon Gerhard Schuler Philipp Lurz | 2016 | World Journal of Cardiology2016，8，8： | 5 |
| 3 | 采用不同导管和技术的去肾交感神经术治疗单纯收缩期高血压:一项随机试验结果显示文摘目前认为单纯收缩期高血压(isolated systolic hypertension,ISH)患者经去肾交感神经术(renal sympathetic denervation,RDN)后血压降低。此结论绝大多数来自单极射频导管消融的研究。但采用新的RDN的数据有限。研究者采用比较3种不同RDN方法的RADIOSOUND-HTN(采用不同RDN导管与技术治疗顽固性高血压患者的三臂随机试验)数据,探讨ISH与RDN反应的可能交互作用。 | Fengler K Rommel KP Lapusca R Blazek S Besler C Hartung P von Roeder M Kresoja KP Desch S Thiele H Lurz P 赵狄 练桂丽 | 2019 | 中华高血压杂志2019，27，7： | 2 |
| 4 | 1, 2, 3- Triazoles and 4, 5-Dihydro-^1H-tetrazol-5- ylidenes from Methyl 3, 3-Diazido-2-cyancacrylate with Amines显示文摘 | Saalfrank R W Wirth U Lurz C J | 1989 | J Org Chem1989，54，17： | 1 |
| 5 | The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells显示文摘 | Prigione A Fauler B Lurz R | | 0，，： | 1 |
| 6 | Percutaneous pulmonary valve implantation:Impact of evolving technology and learning curve on clinical outcome显示文摘 | Lurz P Coats L Khambadkone S | 2008 | Circulation2008，117，15： | 1 |
| 7 | Percutaneous pulmonary valve implantation:An update显示文摘 | Lurz P Bonhoeffer P Taylor AM | 2009 | Expert Rev Cardiovasc Ther2009，7，7： | 1 |
| 8 | The terminally redundant, nonpermuted genome of Listeria bacteriophage A511: a model for the SPOl-like myoviruses of gram-positive bacteria显示文摘 | Klumpp J Dorscht J Lurz R | 2008 | J Bacteriol2008，190，17： | 1 |
| 9 | New ether oxime derivatives of erythromycin A 显示文摘 | Gasc JC D' Ambrieres SG Lurz A | 1991 | J Antibiot1991，44，4： | 1 |
| 10 | Percutaneous pulmonaryvalve implantation j impact of evolving technology andlearning curve on clinical outcome 显示文摘 | Lurz P Coats L Khambadkone S? Nordmeyer J Boud-jemline Y Schievano S | 2008 | Circulation2008，117，： | 1 |
| 11 | Pre-stenting with a bare metal stent before percutaneous pulmonary valve implantation:acute and 1-year outcomes显示文摘 | Nordmeyer J Lurz P Khambadkone S | | 0，，02： | 1 |
| 12 | Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a re- sult of insufficient protein degradation显示文摘 | Waelter S Boedddch A Lurz R | 2001 | Mol Biol Cell2001，12，5： | 1 |
| 13 | Percutaneous pulmonary valve implantation:impact of evolving technology and learning curve on clinical outcome显示文摘 | Lurz P Coats L Khambadkone S | | 0，，15： | 1 |
| 14 | The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells显示文摘 | Prigione A Fauler B Lurz R | | 0，，： | 1 |
| 15 | Sciurus vulgaris显示文摘 | Lurz P W W John G Louise M | 2005 | Mammalian Species2005，，769： | 1 |
| 16 | Percutaneous pulmonary valve implantation : impact of evolving technology and learning curve on clinical outcome显示文摘 | Lurz P Coats L Khambadkone S | 2008 | Circulation2008，117，： | 1 |
| 17 | Percutaneous pulmonary valve implantation impact of evolving technology and learning curve on clinical outcome 显示文摘 | Lurz P Coats L Khambadkone S | 2008 | Circulation2008，117，： | 1 |
| 18 | Percutaneous pulmonary valve im- plantation : an update显示文摘 | Lurz P Bonhoeffer P Taylor AM | 2009 | Expert Rev Cardiovasc Ther2009，7，： | 1 |
| 19 | Accumulation of mutant hun- tington fragments in aggresome-like inclusion bodies as a result of in-sufficient protein degradation显示文摘 | Waeher S Boeddrich A Lurz R | 2001 | Mol Biol Cell2001，12，2： | 1 |
| 20 | The terminally redundant,nonpermuted genome of Listeria bacteriophage A511:a model for the SPO1-like myoviruses of gram-positive bacteria显示文摘 | Klumpp J Dorscht J Lurz R | 2008 | J Bacteriol2008，190，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员